P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE

• Sabina Chiaretti,
• Sabine Blum,
• Thibaut Leguay,
• Marie Balsat,
• Cyril Salek,
• Nicola Fracchiolla,
• Alexandros Spyridonidis,
• Anita Rijneveld,
• Cristina Papayannidis,
• Sofia Ganzha,
• Reetabrata Bhattacharyya,
• Gerhard Zugmaier,
• Isabella Pezzani Grueter,
• Andreas Ochs,
• Alessandro Rambaldi

Affiliations

Sabina Chiaretti

1 Hematology Department of Translational and Precision Medicine, “Sapienza” University, Rome, Italy

Sabine Blum

2 University Hospital and University of Lausanne, Lausanne, Switzerland

Thibaut Leguay

3 University Hospital of Bordeaux, Bordeaux, France

Marie Balsat

4 Hematology Department, Lyon-Sud Hospital, Pierre Bénite, France

Cyril Salek

5 Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Nicola Fracchiolla

6 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Alexandros Spyridonidis

7 University Hospital of Patras, Patra, Greece

Anita Rijneveld

8 Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Cristina Papayannidis

9 IRCCS, Azienda Ospedaliero Universitaria di Bologna, Institute of Hematology “Seràgnoli”, Bologna, Italy

Sofia Ganzha

10 Amgen Ltd, Uxbridge, United Kingdom

Reetabrata Bhattacharyya

11 IQVIA, Bangalore, India

Gerhard Zugmaier

12 Amgen GmbH, Munich, Germany

Isabella Pezzani Grueter

13 Amgen (Europe) GmbH, Rotkreuz, Switzerland

Andreas Ochs

10 Amgen Ltd, Uxbridge, United Kingdom

Alessandro Rambaldi

14 Department of Oncology and Hematology, University of Milan, Milan, Italy